Skip to content

Clinical Trials

Clinical Trials

DOORwaY-90 Study

>Doorway 2Doorway 3Doorway 5

*Using Common Terminology Criteria for Adverse Events v.5.0
BCLC, Barcelona Clinic Liver Cancer, ECOG, Easter Cooperative Oncology Group; EQ-5D-5L, EuroQoL 5-Dimensions 5-Level; FACT-Hep, Functional Assessment of Cancer Therapy-Hepatobiliary; HCC, hepatocellular carcinoma; LI-RADS, Liver Imaging Reporting And Data System; mRECIST, modified Response Evaluation Criteria in Solid Tumors; QoL, quality of life; SIRT, selective internal radiation therapy.

SIR-Spheres® Y-90 resin microspheres are indicated for the treatment of unresectable hepatocellular carcinoma (HCC) or unresectable metastatic liver tumors from primary colorectal cancer (mCRC) in patients refractory to or intolerant of chemotherapy.

SIR-Spheres® is a registered trademark of Sirtex SIR-Spheres Pty Ltd.